Institutional Holder Janus Henderson Discloses 2.19M MDGL Shares (9.9%)
Rhea-AI Filing Summary
Janus Henderson Group plc reports beneficial ownership of 2,191,753 shares of Madrigal Pharmaceuticals common stock, representing 9.9% of the class. The filing breaks this down by reporting persons and subsidiaries: JHIUS may be deemed the beneficial owner of 2,173,828 shares (9.8%), and the reporting tables show shared voting and shared dispositive power over 2,191,753 shares with no sole voting or dispositive power.
The filer certifies these holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power of attorney authorizing named compliance officers to execute required ownership reports on the company’s behalf.
Positive
- Material stake disclosed: Aggregate beneficial ownership of 2,191,753 shares (9.9%) provides clear investor visibility.
- Certifies passive intent: The filing states the shares are held in the ordinary course and not for the purpose of changing control, clarifying intent.
Negative
- None.
Insights
TL;DR: Janus Henderson discloses a near-10% stake in Madrigal with shared voting and dispositive power—material but presented as non-control holdings.
Janus Henderson Group plc reports an aggregate beneficial ownership of 2,191,753 shares (9.9%). The filing specifies 0 shares of sole voting or sole dispositive power and 2,191,753 shares of shared voting and shared dispositive power, consistent with pooled/managed-account ownership structures. JHIUS is identified as an indirect subsidiary potentially deemed beneficial owner of 2,173,828 shares (9.8%). The filer includes an explicit certification that the shares are held in the ordinary course of business and not to influence control, which frames the position as passive rather than activist.
TL;DR: A single institutional group holds a meaningful equity stake near the 10% threshold while disclaiming intent to affect control.
The disclosure is thorough: it identifies reporting entities, quantifies shared voting/dispositive powers, and attaches a power-of-attorney authorizing compliance officers to file on behalf of the parent. For governance review, notable facts are the shared voting control of 2,191,753 shares and the formal statement that holdings were "not acquired or held for the purpose of changing or influencing the control" of the issuer. These elements are relevant for assessing potential influence and for monitoring any future schedule amendments.